Epidemiological and Economic Burden of Alzheimer's Disease: A Systematic Literature Review of Data across Europe and the United States of America
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Background: Alzheimer's disease (AD) weighs heavily on health expenditure and is strongly associated with increasing age. Due to population aging, increasing global prevalence of AD will pose huge challenges to public health and elderly care systems in all countries across the world. Objectives: This study aimed to better understand the burden of AD from a healthcare perspective. Methods: A systematic literature review of journal articles published between January 2002 and December 2012 was performed for studies conducted in France, Germany, Italy, The Netherlands, Spain, the United Kingdom (UK), and the United States of America (USA), using Medline, Embase, and the NHS Economic Evaluation Database. Results: 3,288 references were initially retrieved, and 39 epidemiological and 66 economic publications were selected for data extraction. AD incidence rates greatly varied between countries; however, prevalence was more consistent across all included countries, ranging between 3–7%. Overall, medical costs were lower in France compared to other included countries and increased with AD severity, e.g., direct medical costs per year for mild AD ranged from 5,476 int$ in France to 27,380 int$ in Spain. Limitations, such as heterogeneous methodology and missing data, prevented the comparison of results across studies between countries or the conclusion of any trend over time. Conclusion: This review corroborates previous understanding that AD burden is high for both society and healthcare providers. Limitations regarding study heterogeneity restricted conclusions; further research is required. Stakeholders could benefit from new healthcare strategies addressing both epidemiological and economic aspects of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 1×
“Twelve of the 18 identified studies are presented, as for six studies, data on global prevalence, prevalence by gender and prevalence age were missing [11, 29, 32, 40, 45] or the study [ used secondary – – - ( (cid”
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261 · cited 2×
“[5 1] ca re /P hy si ci an vi si ts /P ar am ed ic al se rv ic es /P ai d ho m e he lp /M ea ls -o nw he el s FT C in co m m un ity 20 ,6 76 (D ) 25 ,0 32”
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Dementia and Alzheimer Disease Incidence: A Prospective Cohort Study
Kukull, W. A., Higdon, R., Bowen, J. D., McCormick, W. C., Teri, L., Schellenberg, G. D., van Belle, G., Jolley, L., & Larson, E. B. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1737 · Cited by 806 · cited 4×
“Finally, seven studies did not clearly define the criteria used for AD diagnosis [31–37]; fove of them only stated that standard criteria were used [31, 33–35, 37], one included patients with previously diagnosed AD, however the diagnosis was established [36], and one did not give any information [32].”
InfluentialGao, S., Hendrie, H. C., Hall, K. S., & Hui, S. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.9.809 · Cited by 754
Rocca, W. A., Petersen, R. C., Knopman, D. S., Hebert, L. E., Evans, D. A., Hall, K. S., Gao, S., Unverzagt, F. W., Langa, K. M., Larson, E. B., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.11.002 · Cited by 498 · cited 3×
“…28, 30], or the Short-CAREquestionnaire[15]beforethefinalADdiagnosis Finally, seven studies did not clearly define the criteria used for AD diagnosis [31–37]; fove of them only stated that standard criteria were used [31, 33–35, , for the Netherlands [43], three for Spain [18, 26, ], one for the UK…”
Incidence and Prevalence of Dementia in the Cardiovascular Health Study
Fitzpatrick, A. L., Kuller, L. H., Ives, D. G., Lopez, O. L., Jagust, W., Breitner, J. C. S., Jones, B., Lyketsos, C., & Dulberg, C. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52058.x · Cited by 438
National estimates of the prevalence of Alzheimer's disease in the United States
Brookmeyer, R., Evans, D. A., Hebert, L., Langa, K. M., Heeringa, S. G., Plassman, B. L., & Kukull, W. A. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.11.007 · Cited by 399
Cited by
Current understanding of Alzheimer’s disease diagnosis and treatment
Weller, J., & Budson, A. (2018) · F1000Research · doi:10.12688/f1000research.14506.1 · Cited by 1,083
“Current therapies enhance cognition without changing the rate of decline in AD (3).”
BackgroundAlzheimer’s disease prevention: from risk factors to early intervention
Crous-Bou, M., Minguillón, C., Gramunt, N., & Molinuevo, J. L. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0297-z · Cited by 687
Alzheimer’s Disease: Epidemiology and Clinical Progression
Tahami Monfared, A. A., Byrnes, M. J., White, L. A., & Zhang, Q. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00338-8 · Cited by 629
“The prevalence of clinically diagnosed AD dementia rises with increasing age [25, 26].”
BackgroundInfluentialEstimating the burden of antimicrobial resistance: a systematic literature review
Naylor, N. R., Atun, R., Zhu, N., Kulasabanathan, K., Silva, S., Chatterjee, A., Knight, G. M., & Robotham, J. V. (2018) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-018-0336-y · Cited by 568
Santos, T. C. D., Gomes, T. M., Pinto, B. A. S., Camara, A. L., & Paes, A. M. D. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01192 · Cited by 389
Beta-amyloid deposition in chronic traumatic encephalopathy
Stein, T. D., Montenigro, P. H., Alvarez, V. E., Xia, W., Crary, J. F., Tripodis, Y., Daneshvar, D. H., Mez, J., Solomon, T., Meng, G., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1435-y · Cited by 291
“Our subjects lived in the United States, and although the prevalence of AD does not vary much between the USA and European countries [47], it is unknown how differences in ethnicity may affect Aβ deposition.”
BackgroundCrous-Bou, M., Gascon, M., Gispert, J. D., Cirach, M., Sánchez-Benavides, G., Falcon, C., Arenaza-Urquijo, E. M., Gotsens, X., Fauria, K., Sunyer, J., et al. (2020) · Environment International · doi:10.1016/j.envint.2020.105546 · Cited by 145
The Many Faces of Astrocytes in Alzheimer's Disease
Monterey, M. D., Wei, H., Wu, X., & Wu, J. Q. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.619626 · Cited by 117
Advance of sporadic Alzheimer's disease animal models
Zhang, L., Chen, C., Mak, M. S., Lu, J., Wu, Z., Chen, Q., Han, Y., Li, Y., & Pi, R. (2020) · Medicinal Research Reviews · doi:10.1002/med.21624 · Cited by 116
García-Morales, V., González-Acedo, A., Melguizo-Rodríguez, L., Pardo-Moreno, T., Costela-Ruiz, V. J., Montiel-Troya, M., & Ramos-Rodríguez, J. J. (2021) · Biomedicines · doi:10.3390/biomedicines9121910 · Cited by 104
Worries About Getting Alzheimer’s: Who’s Concerned?
Cutler, S. J. (2015) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317514568889 · Cited by 82
“Along with increasing incidence and prevalence, AD has become more visible, its symptoms increasingly recognized, and its challenges and burdens better understood and acknowledged.(4) At the same time, the promise of cures and treatment has faded in light of the extremely limited efficacy of pharmaceutical agents and…”
BackgroundD’Cunha, N. M., Georgousopoulou, E. N., Dadigamuwage, L., Kellett, J., Panagiotakos, D. B., Thomas, J., McKune, A. J., Mellor, D. D., & Naumovski, N. (2018) · British Journal of Nutrition · doi:10.1017/s0007114517003452 · Cited by 68
Nkodo, J.-A., Gana, W., Debacq, C., Aidoud, A., Poupin, P., Camus, V., & Fougère, B. (2022) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2022.01.013 · Cited by 36
Ma, J., Initiative, A. D. N., Zhang, W., Tan, L., Wang, H.-F., Wan, Y., Sun, F.-R., Tan, C.-C., Yu, J.-T., & Tan, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9563 · Cited by 23
Metadata
- Authors
- Takizawa, C., Thompson, P. L., van Walsem, A., Faure, C., & Maier, W. C.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2014-12-23
- Volume
- 43
- Issue
- 4
- Pages
- 1271-1284
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1498746154
- Cited by
- 252
- References
- 59
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.